Jefferies Group's MAZE Position Overview
Jefferies Group (via Jefferies Financial Group Inc.) currently holds 55,878 shares of Maze Therapeutics, Inc. (MAZE) worth $1.52 M, representing 0.01% of the portfolio. First purchased in 2026-Q3, this recently established position has been held for 1 quarters.
Based on recent 13F filings, Jefferies Group has initiated a new position in MAZE, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.
Analysis based on 13F filings available since 2013 Q2
Jefferies Group's Maze Therapeutics (MAZE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Maze Therapeutics (MAZE) Trades by Jefferies Group
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q3 2026 | +55,878 | New Buy | 55,878 | $27.18 |
Jefferies Group's Maze Therapeutics Investment FAQs
Jefferies Group first purchased Maze Therapeutics, Inc. (MAZE) in Q3 2026, acquiring 55,878 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jefferies Group has held Maze Therapeutics, Inc. (MAZE) for 1 quarters since Q3 2026.
Jefferies Group's largest addition to Maze Therapeutics, Inc. (MAZE) was in Q3 2026, adding 55,878 shares worth $1.52 M.
According to the latest 13F filing for Q3 2026, Jefferies Group's firm, Jefferies Financial Group Inc., owns 55,878 shares of Maze Therapeutics, Inc. (MAZE), valued at approximately $1.52 M.
As of the Q3 2026 filing, Maze Therapeutics, Inc. (MAZE) represents approximately 0.01% of Jefferies Group's publicly disclosed stock portfolio, making it one of their key holdings.
Jefferies Group's peak holding in Maze Therapeutics, Inc. (MAZE) was 55,878 shares, as reported at the end of Q3 2026.